PRQR insider buying & filings

← All candidates

PRQRProQR Therapeutics N.V.

NasdaqCM · Healthcare · $325.28M

$2.29

-1.08% · Sep 15

One insider buy in the last year — $238.5K in all.
Nothing in the last fortnight.

Last Form 4 Jul 8 · scanned 30s ago

Price · 1Y · daily● 1 buy

▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained

AI brief · from the filings on this pagePro

The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.

▸ Included with Pro →

Market cap

$325.28M

Float

71.3M

50% public

Short % float

Pro

Price / profit

—

not yet profitable

Price / future profit

—

Price / sales

17.7

The buyers

▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions

Chief Executive Officer

de Boer Daniel Anton

Bought $238.5K on Jul 7 — 150,000 sh @ $1.59, held direct, 100% of their stake.

First Form 4 on file

no positions we can measure against the market — the record starts here

Institutional stakes

▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing

4 filingsnewest first

13D/AVan Herk Investments B.v.10.9%Jul 29

13GAberdeen Group plc6.3%Jul 29

13G/AELI LILLY & Co15.6%Jul 24

13D/AVan Herk Investments B.v.10.9%Jun 30

The record

newest first

DateTypeInsiderOf stakeShares @ priceValue

Jul 8BUYde Boer Daniel AntonChief Executive Officer+100%direct150,000 @ $1.59$238.5K

Context

Wall St

$8.25 avg target

+260.3% vs today · 8 analysts · consensus Strong Buy

▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice

Earnings · EPS vs forecast

3 of 4 quarters beat

Q1 '26−$0.15 act+$0.03

Q4 '25−$0.09 act+$0.02

Q3 '25−$0.12 act+$0.05

Q2 '25−$0.14 act−$0.05

Coverage

ProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22%Simply Wall St. · 05-14 Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to DeclineZacks · 05-07 ProQR Therapeutics Unveils New RNA Editing Programs; AX-0810 Phase 1 Target Data Due This QuarterMarketBeat · 04-08 Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical Catalysts

The file stays open

6 filings on record.
The next one will be too.

All candidates

▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice

de Boer Daniel Anton

6 filings on record.The next one will be too.

6 filings on record.
The next one will be too.